Elosulfase alfa - Biologic Drug Details

Summary for elosulfase alfa

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for elosulfase alfa

Established Pharmacologic Class	Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme
Chemical Structure	alpha-Glucosidases

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for elosulfase alfa Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for elosulfase alfa Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Biomarin Pharmaceutical Inc.	VIMIZIM	elosulfase alfa	Injection	125460		2036-07-29	DrugPatentWatch analysis and company disclosures
Biomarin Pharmaceutical Inc.	VIMIZIM	elosulfase alfa	Injection	125460		2035-06-02	DrugPatentWatch analysis and company disclosures
Biomarin Pharmaceutical Inc.	VIMIZIM	elosulfase alfa	Injection	125460		2031-10-13	DrugPatentWatch analysis and company disclosures
Biomarin Pharmaceutical Inc.	VIMIZIM	elosulfase alfa	Injection	125460		2039-08-07	DrugPatentWatch analysis and company disclosures
Biomarin Pharmaceutical Inc.	VIMIZIM	elosulfase alfa	Injection	125460		2029-01-23	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for elosulfase alfa Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Biomarin Pharmaceutical Inc.	VIMIZIM	elosulfase alfa	Injection	125460		2032-10-25	Patent claims search

International Patents for elosulfase alfa

Country	Patent Number	Estimated Expiration
Austria	E524548
Mexico	394708
World Intellectual Property Organization (WIPO)	2012049266
China	110249059
Lithuania	2627183

Supplementary Protection Certificates for elosulfase alfa

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2017024	Norway		PRODUCT NAME: ELOSULFASE ALFA ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV; REG. NO/DATE: EU/1/14/914 20140523
CR 2017 00023	Denmark		PRODUCT NAME: ELOSULFASE ALFA; REG. NO/DATE: EU/1/14/914 20140430
122017000036	Germany		PRODUCT NAME: ELOSULFASE ALFA IN ALLEN SEINEN DURCH DAS GRUNDPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/14/914 20140428
CA 2017 00023	Denmark		PRODUCT NAME: ELOSULFASE ALFA IN ALL FORMS PROTECTED BY THE BASIC PATENT; REG. NO/DATE: EU/1/14/914 20140430
2017/020	Ireland		PRODUCT NAME: ELOSULFASE ALFA IN ALL FORMS PROTECTED BY THE BASIC PATENT; REGISTRATION NO/DATE: EU/1/14/914 20140428

Market Dynamics and Financial Trajectory for Elosulfase Alfa

Last updated: February 13, 2026

Elosulfase alfa, marketed as Vimizim, is a biologic enzyme replacement therapy approved for treating Morquio A syndrome (mucopolysaccharidosis IVA). Its market uptake and financial outlook depend on regulatory approvals, competitive landscape, pricing strategies, and patient population size.

Regulatory Status and Market Adoption

Elosulfase alfa received FDA approval in 2014 and EMA approval in 2015. The treatment targets a rare lysosomal storage disorder caused by a deficiency of the enzyme N-acetylgalactosamine-6-sulfatase, affecting approximately 1 in 200,000 to 300,000 individuals globally.[1] Its approval has enabled access in North America, Europe, and select other markets.

Initial adoption was slow due to high therapy costs and logistical requirements for enzyme infusions. Market penetration has improved as awareness increased and treatment centers expanded.

Market Size and Patient Population

The global Morquio A prevalence is estimated around 2,300 patients.[2] Due to the rarity of the disease, the market remains niche but consistent. Growth hinges on:

• Diagnosis rates: Underdiagnosis remains an issue, with only a fraction of the estimated patient population diagnosed.
• Treatment initiation: Variability in treatment acceptance due to cost and infrastructure.
• Geographic expansion: Entry into emerging markets boosts potential patient numbers.

Pricing Strategy and Revenue Potential

Elosulfase alfa is priced approximately $376,000 annually per patient in the US, based on wholesale acquisition costs.[3] Variations occur across regions due to negotiated discounts, insurance coverage, and reimbursement policies.

Revenue estimates depend on:

• Number of treated patients
• Compliance rates
• Reimbursement success

Assuming treatment of 80% of diagnosed patients within the US, revenue could reach approximately $680 million annually within the country's treated population.

International revenues contribute significantly, with pricing adjustments in Europe and Asia. Pending market access negotiations, global revenues could surpass $1 billion annually.

Competitive Landscape

Elosulfase alfa faces limited competition. Kakkoli (internal enzyme supplementation) has not materialized as an effective alternative. The main competitor is surgical intervention, which does not address systemic enzyme deficiency. Gene therapy efforts are in early stages with potential for future disruption but no approved alternatives currently.

Market Growth Drivers

• Expansion of newborn screening programs for early diagnosis.
• Increased awareness among clinicians.
• Broader reimbursement policies.
• Improvements in infusion convenience and patient quality of life.

Challenges and Risks

• High treatment costs may restrict access.
• Diagnostic delays limit patient identification.
• Manufacturing complexities for biologics can affect supply.
• Regulatory hurdles in emerging markets.

Financial Trajectory Outlook

Projected growth is modest but steady. Market reports estimate compound annual growth rate (CAGR) at around 4-6% over the next five years, driven primarily by international expansion and increasing diagnosis rates.[4]

In the absence of major competitors or disruptive therapies, revenues could approach $1.2 billion globally by 2027, contingent on sustained diagnosis and treatment rates.

Key Takeaways

• Elosulfase alfa is a niche biologic with steady revenue prospects due to disease prevalence.
• Pricing remains high, relying on high per-patient costs to drive total revenues.
• Expansion into emerging markets and improved screening will be critical for growth.
• Competition is limited; future disruption may come from gene therapies.
• Market risks include reimbursement barriers and supply chain challenges.

FAQs

1. What is the current global market size for Elosulfase alfa?
   Approximately 2,300 patients, with estimated global revenues exceeding $900 million annually based on current treatment rates and regional pricing.

2. How does pricing vary across regions?
   In the US, about $376,000 per year per patient; European prices are generally lower due to negotiated discounts, with similar trends in Asia and other markets.

3. What factors influence enrollment in treatment programs?
   Diagnosis rates, patient age, disease severity, healthcare infrastructure, and reimbursement policies.

4. What is the outlook for competition in this space?
   Limited direct competition exists; gene therapy research is ongoing but has not yet resulted in approved alternatives.

5. How could policy changes impact the market?
   Reimbursement adjustments, adoption of newborn screening, and expanded access programs can significantly influence market growth.

References

[1] FDA. Vimizim (elosulfase alfa) approval overview. 2014.
[2] Morquio A disease prevalence data. Orphanet.
[3] Pricing analysis reports. IQVIA, 2022.
[4] Market research forecasts. EvaluatePharma, 2022.